特别提示： 证券代码：300678 证券简称：中科信息 公告编号：2025-062 中科院成都信息技术股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： 现场会议：2025 年 7 月 17 日（星期四）下午 14:30； 网络投票：2025 年 7 月 17 日，其中：通过深圳证券交易所交易系 统进行网络投票的具体时间为 2025 年 7 月 17 日上午 9:15-9:25 和 9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统 进行网络投票的具体时间为 2025 年 7 月 17 日上午 9:15 至下午 15:00 期间的任意时间。 2.现场会议地址：四川省天府新区兴隆街道科智路 1369 号公司南 楼 7 楼 A718 会议室 3.会议方式：现场投票与网络投票相结合的方式 4.会议召集人：公司董事会 5.会议主持人：董事 ...

北京市天元（成都）律师事务所 关于中科院成都信息技术股份有限公司 2025 年第二次临时股东会的法律意见 （2025）天（蓉）意字第 36 号 致：中科院成都信息技术股份有限公司 中科院成都信息技术股份有限公司（以下简称"公司"）2025 年第二次临时股东 会（以下简称"本次股东会"）采取现场投票与网络投票相结合的方式召开，其中现 场会议于 2025 年 7 月 17 日在四川天府新区兴隆街道科智路 1369 号公司南楼 7 楼 A718 会议室召开。北京市天元（成都）律师事务所（以下简称"本所"）接受公司 聘任，指派本所律师参加本次股东会现场会议，并根据《中华人民共和国公司法》《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）以及《中科院成都信息技术股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，就本次股东会的召集、召开程序、出席现场会 议人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《中科院成都信息技术股份有限公司第四届 董事会第二十次会议决议公告》、《中科院成都信息技术股份有限公 ...

证券代码：300678 证券简称：中科信息 公告编号：2025-061 中科院成都信息技术股份有限公司 关于增加经营范围并完成工商登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 中科院成都信息技术股份有限公司（以下简称"公司"）于 2025 年4月30日、2025年5月16日分别召开了第四届董事会第十九次会议、 2025 年第一次临时股东会，审议通过了《关于修订公司章程的议案》， 结合公司经营工作需要，在经营范围中增加了"技术进出口""货物进 出口""业务培训（不含教育培训、职业技能培训等需取得许可的培训）" 三项内容，并按照国家现行的表述规范对公司经营范围表述进行了调整， 未涉及实质性变化。具体内容详见公司于 2025 年 5 月 1 日、2025 年 5 月 16 日在巨潮资讯网披露的相关公告。 目前已完成工商变更登记手续，并取得了成都市市场监督管理局换 发的《营业执照》，本次变更仅涉及经营范围变更，其他事项不变。具 体情况如下： 一、变更后的营业执照信息 1.公司统一社会信用代码：915101007301965784 2.名 称：中科院成都信 ...

Group 1 - The human brain engineering sector experienced a slight increase of 0.41% on July 11, with a total capital outflow of 583.41 million [1] - A total of 21 stocks in the sector rose, while 8 stocks declined [1] - The top-performing stocks included Meihao Medical (+3.83%), Hanwei Technology (+2.72%), and Zhongke Information (+2.27%) [1] Group 2 - The stocks with the largest declines were ST Huatuo (-3.87%), Pulite (-1.94%), and Aipeng Medical (-1.72%) [1] - The overall market sentiment showed a mixed performance with significant capital movements in both rising and falling stocks [1]

Investment Rating - The investment rating for the computer industry is optimistic (maintained) [1] Core Insights - The brain-computer interface (BCI) market has significant potential, with global medical applications expected to reach $40 billion by 2030 and $145 billion by 2040 [5][36] - The technology is maturing, with companies like Neuralink receiving FDA approval for human trials, indicating a shift from concept to practical application [6][8] - Policy support is increasing, with various regions in China implementing plans to accelerate the commercialization of BCI technologies [7][45] Summary by Sections 1. Brain-Computer Interface: Continuous Breakthrough - BCI creates a communication channel between the brain and external devices, enabling direct information exchange [17] - The global BCI market was valued at $2.35 billion in 2023, with a projected CAGR of 16.55% from 2023 to 2033 [35] 2. Policy and Technology Resonance: Bright Commercial Prospects for BCI 2.1 Policy: BCI Medical Pricing Implementation Accelerates Commercialization - Major countries are investing in BCI research, with the U.S. and EU leading in funding and project initiatives [41][44] - China's government has issued multiple directives to guide BCI development, including the establishment of independent pricing for BCI services [45][46] 2.2 Technology: Positive Progress in Clinical Trials, Approaching Industrialization - The BCI system faces numerous technical barriers, particularly in balancing performance and commercial viability [48] - China's BCI sector is rapidly advancing, with increasing publications and patents in the field [51][52] 3. Beneficiary Companies 3.1 Neuralink: Pioneer in Invasive BCI Technology - Neuralink is leading in invasive BCI technology, having initiated human trials and planning further patient implants [55][66] 3.2 Strong Brain Technology: Leader in Non-Invasive BCI - Strong Brain Technology focuses on non-invasive BCI solutions, having developed multiple products and secured significant funding [67][69] 3.3 Rock Mountain Technology: Forward-Looking Layout of Brainwave Large Models - Rock Mountain Technology is developing brainwave large models to enhance human-computer interaction systems [80]

Group 1 - The brain-computer interface concept sector rose by 0.74%, ranking 8th among concept sectors, with 17 stocks increasing in value [1] - Leading gainers in the sector included Jihua Group, Entropy Technology, and Beiyikang, which rose by 7.59%, 5.92%, and 4.33% respectively [1] - The sector experienced a net inflow of 366 million yuan, with 18 stocks receiving net inflows, and 12 stocks seeing inflows exceeding 10 million yuan [1][2] Group 2 - Jihua Group had the highest net inflow of 331 million yuan, followed by Innovative Medical, Chengyitong, and Zhongke Information with net inflows of 162 million yuan, 77.97 million yuan, and 36.04 million yuan respectively [1][2] - The net inflow ratios for Jihua Group, Chengyitong, and Zhongke Information were 13.23%, 10.52%, and 8.87% respectively [2] - The trading volume and turnover rates for leading stocks in the sector were significant, with Jihua Group showing a turnover rate of 13.84% [2][3]

Core Points - Zhang Li, a board member of the company, resigned due to a change in responsibilities at the controlling shareholder, the Chinese Academy of Sciences Holdings Co., Ltd [1] - The company held its 20th meeting of the 4th board on June 30, 2025, where it approved the proposal to elect Pei Xiaofeng as a non-independent director candidate [1] - The election of the new director will be submitted for shareholder approval and will not exceed the limit of management personnel on the board [1] Candidate Profile - Pei Xiaofeng, born in June 1978, holds a Master's degree in Business Administration from the University of Chinese Academy of Sciences and is a certified public accountant [4] - She has held various positions within the Chinese Academy of Sciences Holdings Co., Ltd, including Senior Manager and General Manager of the Financial Management Department [4] - Pei Xiaofeng does not hold shares in the company and has no related relationships with shareholders owning more than 5% of the company [4]

Core Points - The document outlines the procedures and regulations for the resignation of directors and senior management at the company, aiming to maintain governance stability and protect the rights of shareholders [1][2][3] - It specifies the conditions under which directors can resign, including the requirement to submit a written resignation report and the timeline for the company to disclose this information [2][3] - The document emphasizes the responsibilities of departing directors and senior management regarding the handover of company assets and information, as well as their ongoing obligations to the company post-resignation [3][4][6] Resignation Procedures - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company [2] - If a resignation leads to a board composition below legal requirements, the departing directors must continue to fulfill their duties until new directors are appointed [2] - The company must complete the election of new directors within 60 days of a resignation to ensure compliance with legal and regulatory requirements [3] Handover Obligations - Departing directors and senior management must complete the handover of company documents and assets within three working days after their resignation [3] - If there are outstanding public commitments, the company can require a written plan for fulfillment from the departing personnel [3] - Departing personnel are obligated to cooperate with the company in post-resignation audits and investigations regarding significant matters during their tenure [3][4] Shareholding Management - Departing directors and senior management are prohibited from transferring their shares within six months of resignation [4] - There are restrictions on the amount of shares that can be sold during their term and within six months post-resignation, not exceeding 25% of their total holdings [4] - The company secretary is responsible for monitoring shareholding changes and reporting to regulatory authorities as necessary [4] Accountability Mechanism - The board will review and determine accountability measures for any breaches of obligations by departing directors and senior management [6] - Departing personnel can appeal the board's decisions regarding accountability within 15 days of notification [6] - The document stipulates that any unresolved issues will be governed by relevant national laws and the company's articles of association [6]

第三条 公司董事可在任期届满前辞职，辞职时应向公司提交书面辞职报告， 说明辞职原因。公司收到辞职报告之日起，辞职生效，公司将在两个交易日内披 露有关情况。 如涉及独立董事辞职，需说明是否对公司治理及独立性构成重大影响。如因 董事的辞职导致公司董事会低于法定最低人数时，或者独立董事辞职导致独立董 事人数少于董事会成员的三分之一或独立董事中没有会计专业人士时，在改选出 的董事就任前，原董事仍应当依照法律、行政法规、部门规章和 《公司章程》规 定，履行董事职务。 证券代码：300678 证券简称：中科信息 中科院成都信息技术股份有限公司 董事、高级管理人员离职管理制度 （2024 年 7 月） 第一章 总则 第一条 为规范中科院成都信息技术股份有限公司（以下简称"公司"）董 事离职程序，维护公司治理结构稳定、有序，维护公司和股东的合法权益，依据 《中华人民共和国公司法》（以下简称 " 《公司法》"）、《中华人民共和国证 券法》（以下简称 " 《证券法》"）、《上市公司治理准则》《深圳证券交易所 股票上市规则》等相关法律法规以及《中科院成都信息技术股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，制定本制度 ...

证券代码：300678 证券简称：中科信息 公告编号：2025-058 中科院成都信息技术股份有限公司 关于补选非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 附件：裴小凤女士简历 特此公告。 中科院成都信息技术股份有限公司 公司于2025年6月30日召开第四届董事会第二十次会议，审议通过 了《关于补选第四届董事会非独立董事的议案》，经控股股东中国科学 院控股有限公司推荐，董事会提名委员会资格审查通过，董事会同意提 名裴小凤女士（简历详见附件）为公司第四届董事会非独立董事候选人， 任期自股东会审议通过之日起至公司第四届董事会届满之日止。本事项 尚需提交股东会审议。 董事会 中科院成都信息技术股份有限公司（以下简称"公司"）董事张莉 女士因在控股股东中国科学院控股有限公司的工作职责调整原因申请 辞去公司董事、战略委员会委员、薪酬与考核委员会委员职务。具体内 容详见公司于2025年5月22日在巨潮资讯网披露的《关于董事辞职的公 告》（公告编号：2025-053）。 本次补选董事后，不会导致董事会中兼任公司高级管理人员的董事 人数总计超过公司董事总 ...